Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10959947 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
US10959948 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
US10959949 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
US10959946 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
US10688046 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
US10493028 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) |
Market Authorisation Date: 26 January, 2018
Treatment: Treatment of staphylococcal enterocolitis; Treatment of c. difficile-associated diarrhea
Dosage: FOR SOLUTION;ORAL
13
United States
2
European Union
1
Japan
1
Australia
1
Spain
1
Canada
1
China
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10188697 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US10039804 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US10849956 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US11517609 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) |
Market Authorisation Date: 15 February, 2019
Treatment: Method of treating bacterial infections
Dosage: SOLUTION;INTRAVENOUS
9
United States
4
European Union
2
Portugal
2
Spain
2
Croatia
2
Japan
2
Slovenia
2
Hungary
2
Poland
2
RS
2
Denmark
1
Singapore
1
Brazil
1
Costa Rica
1
Colombia
1
Philippines
1
Mexico
1
China
1
Korea, Republic of
1
Tunisia
1
EA
1
South Africa
1
Canada
1
Saudi Arabia
1
Israel
1
Chile
1
Australia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic